Contact Us
Drug Search Results
More Filters [+]

Aliskiren

Alternative Names: aliskiren, tekturna, spp100, aliskirenhemifumarat, amturnide, tekamlo, valturna, rasilamlo
Latest Update: 2024-12-05
Latest Update Note: Clinical Trial Update

Product Description

Aliskiren is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. (Sourced from: https://www.mayoclinic.org/drugs-supplements/aliskiren-oral-route/description/drg-20070895)

Mechanisms of Action: Renin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Latvia | Lithuania | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Myocardial Infarction | Hypertension | Stroke | Hypertension | Acute Myeloid Leukemia | Hypertension

Known Adverse Events: Diarrhea | Edema | Nasopharyngitis | Pharyngitis

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aliskiren

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

10/14/2024

News Article

 Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

09/05/2024

News Article

 Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

05/09/2024

News Article

 Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

04/24/2024

News Article

 Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions